Eurofins Scientific announced the acquisition of assets to establish a fully-equipped, laboratory campus in Genome Valley, Hyderabad. The acquisition includes a facility capable of supporting large global and Indian pharmaceutical clients as well as small biotech companies in the areas of synthetic organic chemistry, analytical R&D, bioanalytical services (for both large and small molecules), in-vivo pharmacology, safety toxicology and formulation R&D. The laboratories occupy over 90,000 ft2.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
56.68 EUR | +0.32% | +0.07% | -3.90% |
04-29 | CAC40: France's rating maintained = non-event | CF |
04-29 | CAC40: starts the week slightly up, crosses the 8100 mark | CF |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-3.90% | 11.78B | |
+13.70% | 81.4B | |
-29.20% | 70.18B | |
+9.72% | 29.08B | |
-11.43% | 16.97B | |
-0.43% | 16.96B | |
-0.31% | 15.26B | |
+3.42% | 12.41B | |
-30.70% | 11.95B | |
-6.75% | 11.93B |
- Stock Market
- Equities
- ERF Stock
- News Eurofins Scientific SE
- Eurofins Scientific Expands Presence in Indian Pharmaceutical Market with New Hyderabad Campus